211 related articles for article (PubMed ID: 9653060)
1. Interspecies scaling of clearance and volume of distribution for horse antivenom F(ab')2.
Bazin-Redureau M; Pepin S; Hong G; Debray M; Scherrmann JM
Toxicol Appl Pharmacol; 1998 Jun; 150(2):295-300. PubMed ID: 9653060
[TBL] [Abstract][Full Text] [Related]
2. Interspecies scaling of clearance and volume of distribution for digoxin-specific Fab.
Grene-Lerouge NA; Bazin-Redureau MI; Debray M; Scherrmann JM
Toxicol Appl Pharmacol; 1996 May; 138(1):84-9. PubMed ID: 8658517
[TBL] [Abstract][Full Text] [Related]
3. Immunoreactivity and pharmacokinetics of horse anti-scorpion venom F(ab')2-scorpion venom interactions.
Pépin-Covatta S; Lutsch C; Grandgeorge M; Lang J; Scherrmann JM
Toxicol Appl Pharmacol; 1996 Nov; 141(1):272-7. PubMed ID: 8917700
[TBL] [Abstract][Full Text] [Related]
4. Initial volume of a drug before it reaches the volume of distribution: pharmacokinetics of F(ab')2 antivenoms and other drugs.
Sevcik C; Salazar V; Díaz P; D'Suze G
Toxicon; 2007 Oct; 50(5):653-65. PubMed ID: 17689580
[TBL] [Abstract][Full Text] [Related]
5. Production of anti-horse antibodies induced by IgG, F(ab')2 and Fab applied repeatedly to rabbits. Effect on antivenom pharmacokinetics.
Vázquez H; Olvera F; Alagón A; Sevcik C
Toxicon; 2013 Dec; 76():362-9. PubMed ID: 24047962
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and interspecies scaling of recombinant human factor VIII.
Mordenti J; Osaka G; Garcia K; Thomsen K; Licko V; Meng G
Toxicol Appl Pharmacol; 1996 Jan; 136(1):75-8. PubMed ID: 8560482
[TBL] [Abstract][Full Text] [Related]
7. Interspecies pharmacokinetic scaling of oltipraz in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics.
Bae SK; Lee SJ; Kim YG; Kim SH; Kim JW; Kim T; Lee MG
Biopharm Drug Dispos; 2005 Apr; 26(3):99-115. PubMed ID: 15723427
[TBL] [Abstract][Full Text] [Related]
8. Snake F(ab')2 antivenom from hyperimmunized horse: pharmacokinetics following intravenous and intramuscular administrations in rabbits.
Pepin S; Lutsch C; Grandgeorge M; Scherrmann JM
Pharm Res; 1995 Oct; 12(10):1470-3. PubMed ID: 8584483
[TBL] [Abstract][Full Text] [Related]
9. Interspecies pharmacokinetic scaling of DA-8159, a new erectogenic, in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics.
Shim HJ; Kim YC; Lee JH; Kwon JW; Kim WB; Kim YG; Kim SH; Lee MG
Biopharm Drug Dispos; 2005 Oct; 26(7):269-77. PubMed ID: 15991256
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of a F(ab')2 scorpion antivenom administered intramuscularly in healthy human volunteers.
Vázquez H; Chávez-Haro A; García-Ubbelohde W; Paniagua-Solís J; Alagón A; Sevcik C
Int Immunopharmacol; 2010 Nov; 10(11):1318-24. PubMed ID: 20849955
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics in rabbits and anti-sphingomyelinase D neutralizing power of Fab, F(ab')(2), IgG and IgG(T) fragments from hyper immune equine plasma.
Vázquez H; Olvera F; Paniagua-Solís J; Alagón A; Sevcik C
Int Immunopharmacol; 2010 Apr; 10(4):447-54. PubMed ID: 20093203
[TBL] [Abstract][Full Text] [Related]
12. Development and validation of an antigen-binding capture ELISA for native and putrescine-modified anti-tetanus F(ab')2 fragments for the assessment of the cellular uptake and plasma kinetics of the antibodies.
Welfringer F; d'Athis P; Scherrmann JM; Hervé F
J Immunol Methods; 2005 Dec; 307(1-2):82-95. PubMed ID: 16305797
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of monoclonal immunoglobulin G1, F(ab')2, and Fab' in mice.
Covell DG; Barbet J; Holton OD; Black CD; Parker RJ; Weinstein JN
Cancer Res; 1986 Aug; 46(8):3969-78. PubMed ID: 3731067
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of 125I-labelled Walterinnesia aegyptia venom and its distribution of the venom and its toxin versus slow absorption and distribution of IGG, F(AB')2 and F(AB) of the antivenin.
Ismail M; Abd-Elsalam MA; Al-Ahaidib MS
Toxicon; 1998 Jan; 36(1):93-114. PubMed ID: 9604285
[TBL] [Abstract][Full Text] [Related]
15. Interspecies scaling of the monoclonal anti-EGF receptor ior EGF/r3 antibody disposition using allometric paradigm: is it really suitable?
Ducongé J; Fernández-Sánchez E; Alvarez D
Biopharm Drug Dispos; 2004 May; 25(4):177-86. PubMed ID: 15108220
[TBL] [Abstract][Full Text] [Related]
16. Preclinical assessment of immunoreactivity of a new purified equine F(ab')2 against European viper venom.
Pepin-Covatta S; Lutsch C; Lang J; Scherrmann JM
J Pharm Sci; 1998 Feb; 87(2):221-5. PubMed ID: 9519157
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of a F(ab')2 scorpion antivenom in healthy human volunteers.
Vázquez H; Chávez-Haro A; García-Ubbelohde W; Mancilla-Nava R; Paniagua-Solís J; Alagón A; Sevcik C
Toxicon; 2005 Dec; 46(7):797-805. PubMed ID: 16197974
[TBL] [Abstract][Full Text] [Related]
18. Effect of antivenom on venom pharmacokinetics in experimentally envenomed rabbits: toward an optimization of antivenom therapy.
Rivière G; Choumet V; Audebert F; Sabouraud A; Debray M; Scherrmann JM; Bon C
J Pharmacol Exp Ther; 1997 Apr; 281(1):1-8. PubMed ID: 9103473
[TBL] [Abstract][Full Text] [Related]
19. Comparative pharmacokinetics of enrofloxacin in mice, rats, rabbits, sheep, and cows.
Bregante MA; Saez P; Aramayona JJ; Fraile L; Garcia MA; Solans C
Am J Vet Res; 1999 Sep; 60(9):1111-6. PubMed ID: 10490081
[TBL] [Abstract][Full Text] [Related]
20. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of humanized monoclonal anti-IL-13 antibodies with different IL-13 neutralization mechanisms.
Vugmeyster Y; Szklut P; Tchistiakova L; Abraham W; Kasaian M; Xu X
Int Immunopharmacol; 2008 Mar; 8(3):477-83. PubMed ID: 18279802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
